Bosutinib in the treatment of chronic myelogenous leukemia

Clinical Advances in Hematology and Oncology

Volumn 10, Issue 11, 2012, Pages 736-737

  Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE;

CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; HUMAN; MULTICENTER STUDY (TOPIC); NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; BENZAMIDES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NITRILES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINOLINES;

EID: 84872713554     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486-3492.
2. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119:3403-3412.
3. Gambacorti-Passerini C, Lipton JH, Tee GY, et al. BELA trial update: bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up. J Clin Oncol (ASCO Annual Meeting Abstracts). 2012;30: Abstract 6512.
4. US Food and Drug Administration. Highlights of Prescribing Information for Bosulif. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl. pdf. Accessed October 23, 2012.